Eero Rautalahti appointed to Board of Directors of FIT Biotech
An Extraordinary Meeting of Shareholders of FIT Biotech has appointed Eero Rautalahti, a Partner of McCarthy Denning, a non-executive member of the Board of Directors.
Eero has practiced law in London since 1995. He has advised on numerous IPOs (initial public offerings) on several different markets, including primary listings abroad and early-stage IPOs.
Chairman of the Board of FIT Biotech, Juha Vapaavuori: “Eero Rautalahti provides the Company’s board with valuable competence and additional experience from the field of international business law. We warmly welcome Eero to reinforce the board of FIT Biotech Oy.”
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines. FIT Biotech’s series K shares are admitted to public trading at Nasdaq OMX First North.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
DATE 10/02/2017
